{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:59:57Z","timestamp":1794862797723,"version":"4.9.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011099","name":"Deutsche Gesellschaft f\u00fcr Internationale Zusammenarbeit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/21645515.2026.2628424","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:46:41Z","timestamp":1772725601000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9345-3630","authenticated-orcid":false,"given":"Monica","family":"Moschioni","sequence":"first","affiliation":[{"name":"Medicines Patent Pool","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafay Anwer","family":"Siraji","sequence":"additional","affiliation":[{"name":"TT Consultants Services LLC","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Dissard","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Segafredo","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Mutungi","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashima","family":"Jain","sequence":"additional","affiliation":[{"name":"TT Consultants Services LLC","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Thakur","sequence":"additional","affiliation":[{"name":"TT Consultants Services LLC","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Maurya","sequence":"additional","affiliation":[{"name":"TT Consultants Services LLC","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ike","family":"James","sequence":"additional","affiliation":[{"name":"Medicines Patent Pool","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/08971900211009650"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2507"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00306-8"},{"key":"e_1_3_4_6_1","unstructured":"Swan T. Local vaccine production: harnessing its potential for equity [Internet]. 2023. https:\/\/avac.org\/wp-content\/uploads\/2023\/11\/LabToJab-LocalVaxProduction-Nov2023.pdf."},{"key":"e_1_3_4_7_1","unstructured":"WHO Pandemic Agreement [Internet]. 2025. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA78\/A78_R1-en.pdf."},{"key":"e_1_3_4_8_1","unstructured":"Medicines Patent Pool & World Health Organization. Update on the mRNA technology transfer programme [Internet]. 2024 [accessed 2025 Mar 31]. https:\/\/healthpolicy-watch.news\/update-on-the-mrna-technology-transfer-programme\/."},{"key":"e_1_3_4_9_1","unstructured":"Midgley M. New research hubs will improve vaccine access in low- and middle-income countries [Internet]. 2023 Nov 6. University College London. https:\/\/www.ucl.ac.uk\/news\/2023\/nov\/new-research-hubs-will-improve-vaccine-access-low-and-middle-income-countries."},{"key":"e_1_3_4_10_1","unstructured":"Regionalized Vaccine Manufacturing Collaborative [Internet]. [accessed Jan 2026]. https:\/\/initiatives.weforum.org\/regionalized-vaccine-manufacturing-collaborative\/home"},{"key":"e_1_3_4_11_1","unstructured":"CEPI. Biontech and Cepi expand partnership to strengthen Africa\u2019s mRNA vaccine ecosystem [Internet]. 2024 May 29. https:\/\/cepi.net\/biontech-and-cepi-expand-partnership-strengthen-africas-mrna-vaccine-ecosystem."},{"key":"e_1_3_4_12_1","unstructured":"CEPI. Cepi and Moderna harness mRNA technology to advance 100 days mission [Internet]. 2023. https:\/\/cepi.net\/cepi-and-moderna-harness-mrna-technology-advance-100-days-mission-0."},{"key":"e_1_3_4_13_1","unstructured":"CEPI. Cepi and Bio Farma partnership boosts rapid response vaccine manufacturing for the global South [Internet]. 2023. https:\/\/cepi.net\/cepi-and-bio-farma-partnership-boosts-rapid-response-vaccine-manufacturing-global-south."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02444-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071972"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-025-02645-6"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02002-z"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13060601"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1547025"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172691"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.020409"},{"key":"e_1_3_4_22_1","unstructured":"ClinicalTrials.gov [Internet]. https:\/\/clinicaltrials.gov\/."},{"key":"e_1_3_4_23_1","unstructured":"Beacon Intelligence [Internet]. https:\/\/beacon-intelligence.com\/."},{"key":"e_1_3_4_24_1","unstructured":"International Clinical Trials Registry Platform (ICTRP) [Internet]. https:\/\/www.who.int\/tools\/clinical-trials-registry-platform."},{"key":"e_1_3_4_25_1","unstructured":"ANZCTR [Internet]. https:\/\/www.anzctr.org.au\/TrialSearch.aspx."},{"key":"e_1_3_4_26_1","unstructured":"Chinese Clinical Trial Registry [Internet]. https:\/\/www.chictr.org.cn\/searchprojEN.html."},{"key":"e_1_3_4_27_1","unstructured":"European Medicines Agency (EMA) [Internet]. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-information-system."},{"key":"e_1_3_4_28_1","unstructured":"EUCTR [Internet]. https:\/\/www.clinicaltrialsregister.eu\/."},{"key":"e_1_3_4_29_1","unstructured":"CTRI [Internet]. https:\/\/ctri.nic.in\/Clinicaltrials\/login.php."},{"key":"e_1_3_4_30_1","unstructured":"German Clinical Trials Register [Internet]. https:\/\/www.bfarm.de\/EN\/BfArM\/Tasks\/German-Clinical-Trials-Register\/_node.html."},{"key":"e_1_3_4_31_1","unstructured":"ISRCTN registry [Internet]. https:\/\/www.isrctn.com\/."},{"key":"e_1_3_4_32_1","unstructured":"CCMO [Internet]. https:\/\/www.onderzoekmetmensen.nl\/en\/search."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032700"},{"key":"e_1_3_4_35_1","unstructured":"IHME|GHDx [Internet]. 2023. https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00757-8"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00685-8"},{"key":"e_1_3_4_38_1","unstructured":"World Bank Country and Lending Groups [Internet]. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105424"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/bjbs.2025.14557"},{"key":"e_1_3_4_41_1","first-page":"463","article-title":"Updated WHO list of emerging pathogens for a potential future pandemic: Implications for public health and global preparedness","volume":"32","author":"Ukoaka BM","year":"2024","unstructured":"Ukoaka BM, Okesanya OJ, Daniel FM, Ahmed MM, Udam NG, Wagwula PM, Adigun OA, Udoh RA, Peter IG, Lawal H. Updated WHO list of emerging pathogens for a potential future pandemic: Implications for public health and global preparedness. Infez Med. 2024;32:463.","journal-title":"Infez Med"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00095-3"},{"key":"e_1_3_4_43_1","unstructured":"Moderna. Moderna receives US FDA approval for RSV vaccine mRESVIA. 2024."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416779"},{"key":"e_1_3_4_45_1","unstructured":"Beaney A. Moderna scraps mRNA vaccine in congenital CMV on phase III failure [Internet]. 2025. https:\/\/www.clinicaltrialsarena.com\/news\/moderna-scraps-mrna-vaccine-in-congenital-cmv-on-phase-iii-failure\/."},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-20-0571"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002260"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020430"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2025.2596674"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.11.001"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106699"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15030668"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186582"},{"key":"e_1_3_4_54_1","unstructured":"Immorna receives IND clearance to conduct a phase 1 study of JCXH-105 a self-replicating RNA-based shingles vaccine [Internet]. 2023 Jan 09. https:\/\/en.prnasia.com\/releases\/global\/immorna-receives-ind-clearance-to-conduct-a-phase-1-study-of-jcxh-105-a-self-replicating-rna-based-shingles-vaccine-389839.shtml."},{"key":"e_1_3_4_55_1","unstructured":"Immorna receives grant from Bill & Melinda Gates Foundation to support its mRNA RSV vaccine clinical development [Internet]. 2024 Aug 26. https:\/\/www.prnewswire.com\/news-releases\/immorna-receives-grant-from-bill\u2013melinda-gates-foundation-to-support-its-mrna-rsv-vaccine-clinical-development-302229974.html."},{"key":"e_1_3_4_56_1","unstructured":"MODERNA. Moderna analyst day highlights pipeline progress and business strategy updates [Internet]. 2025 Nov 21. https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=5758345706655596&symbol=MRNA."}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2026.2628424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:46:46Z","timestamp":1772725606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2026.2628424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/21645515.2026.2628424"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2026.2628424","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2628424"}}